Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sequential chemotherapy and blinatumomab for MRD response in Philadelphia chromosome-negative B-cell precursor acute lymphoblastic leukemia
2017-004251-23Phase 2Completed
- Sponsor
- GIMEMA
- Start
- Jun 2021
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, scFv Fragments → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of blinatumomab in acute lymphoblastic leukemia (ALL), sponsored by GIMEMA. Primary endpoint: Early minimal residual disease negativity rate. Started Jun 2021; status: completed.
02
Drugs
blinatumomab
03
Conditions
acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on 2017-004251-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-004251-23.